Segall Bryant & Hamill’s Inspire Medical Systems INSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-38,707
Closed -$12.6M 601
2023
Q2
$12.6M Buy
38,707
+179
+0.5% +$51.1K 0.13% 200
2023
Q1
$9.02M Buy
38,528
+481
+1% +$122K 0.1% 244
2022
Q4
$9.58M Sell
38,047
-14,083
-27% -$3M 0.11% 229
2022
Q3
$9.25M Buy
52,130
+1,041
+2% +$209K 0.11% 222
2022
Q2
$9.33M Buy
51,089
+15,239
+43% +$3.04M 0.11% 212
2022
Q1
$9.2M Sell
35,850
-11,413
-24% -$2.61M 0.09% 230
2021
Q4
$10.9M Buy
47,263
+2,199
+5% +$537K 0.1% 202
2021
Q3
$10.5M Buy
45,064
+1,198
+3% +$250K 0.1% 206
2021
Q2
$8.48M Sell
43,866
-17,095
-28% -$3.39M 0.08% 237
2021
Q1
$12.6M Buy
60,961
+16,495
+37% +$3.51M 0.12% 188
2020
Q4
$8.36M Sell
44,466
-780
-2% -$128K 0.09% 218
2020
Q3
$5.84M Buy
45,246
+33,551
+287% +$3.7M 0.08% 239
2020
Q2
$1.02M Buy
11,695
+354
+3% +$27.2K 0.02% 431
2020
Q1
$684K Buy
11,341
+3,236
+40% +$239K 0.01% 517
2019
Q4
$601K Sell
8,105
-496
-6% -$31.9K 0.01% 625
2019
Q3
$525K Buy
+8,601
New +$566K 0.01% 644

Other funds holding INSP

Segall Bryant & Hamill's INSP Position: Q3 2023 in Review

Segall Bryant & Hamill sold out of Inspire Medical Systems (INSP) in Q3 2023, closing a stake of 38,707 shares — an estimated $12.6M sold.

Segall Bryant & Hamill first reported a position in INSP in Q3 2019 and held it in 16 quarters. The position peaked at $12.6M in Q1 2021. 364 funds tracked by Wall St. Rank hold INSP as of Q3 2023.

  • Segall Bryant & Hamill reported no remaining Inspire Medical Systems position as of Q3 2023 after selling out during the quarter.
  • Segall Bryant & Hamill sold 38,707 Inspire Medical Systems shares in Q3 2023, an estimated $12.6M.
  • Segall Bryant & Hamill first reported a position in Inspire Medical Systems in Q3 2019 and held it in 16 quarters.
  • Segall Bryant & Hamill's Inspire Medical Systems position peaked at $12.6M in Q1 2021.
  • 364 funds tracked by Wall St. Rank held Inspire Medical Systems as of Q3 2023.

Based on Segall Bryant & Hamill's 13F filing for Q3 2023, filed 9 Nov 2023.